AlloStim
AlloStim is a biological therapy with 12 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
6
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
58.3%
7 of 12 finished
41.7%
5 ended early
0
trials recruiting
12
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer
Immunotherapy for Third Line Metastatic Colorectal Cancer
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
Universal Anti-Viral Vaccine for Healthy Elderly Adults
Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck
Clinical Trials (12)
Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer
Immunotherapy for Third Line Metastatic Colorectal Cancer
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
Universal Anti-Viral Vaccine for Healthy Elderly Adults
Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck
An Individualized Anti-Cancer Vaccine Study in Patients With HCC
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer
In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients
AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer
An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects
All 12 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 12